A Phase 1 interventional study of Zanubrutinib and Rifabutin in Healthy and Male, sponsored by BeiGene. Completed at 1 site in United States. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-26.
Sponsored by BeiGene · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study was to determine the effect of the moderate cytochrome P450 3A (CYP3A) inducer rifabutin on the pharmacokinetics (PK) of zanubrutinib in healthy males.
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Day 1: zanubrutinib Days 3 to 10: rifabutin Day 11: zanubrutinib and rifabutin
Drug: Zanubrutinib · Drug: Rifabutin
Single oral dose of 320 mg
Also known as: BGB-3111, Brukinsa
Oral dose of 300 mg once daily
Area Under the Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Zanubrutinib
Time frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
AUC From Time Zero to Infinity (AUC0-∞) of Zanubrutinib
Time frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
Maximum Observed Plasma Concentration (Cmax) of Zanubrutinib
Time frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
Time to the Maximum Observed Plasma Concentration (Tmax) of Zanubrutinib
Time frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
Time of the Last Quantifiable Concentration (Tlast) of Zanubrutinib
Time frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
Apparent Terminal Elimination Half-life (t1/2) of Zanubrutinib
Time frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
Apparent Oral Clearance (CL/F) of Zanubrutinib
Time frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
Apparent Volume of Distribution (Vz/F) of Zanubrutinib
Time frame: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 36 hours postdose on Days 1 and 11
Number of Participants Experiencing Adverse Events (AEs)
Adverse events (AEs) and serious adverse events included for summary, AEs that start during or after the first dose, or start prior to the first dose and increases in severity after the first dose, including vital signs, physical examination, electrocardiogram, and laboratory parameters
Time frame: From the date of first study drug administration to 30 days after last dose (up to 3.5 months)
This was a single-center study with dosing in a fixed sequence. A total of 13 participants were enrolled and 12 completed the study.
| Milestone | Zanubrutinib + Rifabutin |
|---|---|
| Started | 13 |
| Completed | 13 |
| Not completed | 0 |
| Milestone | Zanubrutinib + Rifabutin |
|---|---|
| Started | 13 |
| Completed | 13 |
| Not completed | 0 |
| Milestone | Zanubrutinib + Rifabutin |
|---|---|
| Started | 13 |
| Completed | 12 |
| Not completed | 1 |
| Withdrew: Lost to follow-up | 1 |
| h*ng/mL | Zanubrutinib | Zanubrutinib + Rifabutin |
|---|---|---|
| Area Under the Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Zanubrutinib | 2700 ± 24.8 | 1530 ± 21.4 |
| h*ng/mL | Zanubrutinib | Zanubrutinib + Rifabutin |
|---|---|---|
| AUC From Time Zero to Infinity (AUC0-∞) of Zanubrutinib | 2780 ± 23.3 | 1590 ± 22.2 |
| ng/mL | Zanubrutinib | Zanubrutinib + Rifabutin |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Zanubrutinib | 489 ± 38.1 | 253 ± 33.7 |
| Hours | Zanubrutinib | Zanubrutinib + Rifabutin |
|---|---|---|
| Time to the Maximum Observed Plasma Concentration (Tmax) of Zanubrutinib | 1.50 (1.00 to 4.02) | 2.00 (1.00 to 8.00) |
| Hours | Zanubrutinib | Zanubrutinib + Rifabutin |
|---|---|---|
| Time of the Last Quantifiable Concentration (Tlast) of Zanubrutinib | 36.0 (24.0 to 36.0) | 36.0 (24.0 to 36.0) |
| Hours | Zanubrutinib | Zanubrutinib + Rifabutin |
|---|---|---|
| Apparent Terminal Elimination Half-life (t1/2) of Zanubrutinib | 7.24 ± 3.10 | 7.00 ± 4.46 |
| Liters/hour | Zanubrutinib | Zanubrutinib + Rifabutin |
|---|---|---|
| Apparent Oral Clearance (CL/F) of Zanubrutinib | 115 ± 23.3 | 201 ± 22.2 |
| Liters | Zanubrutinib | Zanubrutinib + Rifabutin |
|---|---|---|
| Apparent Volume of Distribution (Vz/F) of Zanubrutinib | 1080 ± 68.4 | 1750 ± 70.9 |
Adverse events (AEs) and serious adverse events included for summary, AEs that start during or after the first dose, or start prior to the first dose and increases in severity after the first dose, including vital signs, physical examination, electrocardiogram, and laboratory parameters
| Participants | Zanubrutinib on Day 1 | Rifabutin on Days 3 to 10 | Zanubrutinib + Rifabutin on Day 11 |
|---|---|---|---|
| At least 1 treatment-emergent adverse event (TEAE) | 1 | 6 | 0 |
| Serious adverse events | 0 | 0 | 0 |
| Vital sign TEAEs | 0 | 0 | 0 |
| Physical examination TEAEs | 0 | 0 | 0 |
| Electrocardiogram TEAEs | 0 | 0 | 0 |
| Laboratory-related TEAEs | 0 | 0 | 0 |
Collected over From the date of first study drug administration to 30 days after last dose (up to 3.5 months). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zanubrutinib on Day 1 | 0/13 (0%) | 0/13 (0%) | 1/13 (7.7%) |
| Rifabutin on Days 3 to 10 | 0/13 (0%) | 0/13 (0%) | 6/13 (46.2%) |
| Zanubrutinib + Rifabutin on Day 11 | 0/13 (0%) | 0/13 (0%) | 0/13 (0%) |
| Event | Zanubrutinib on Day 1 | Rifabutin on Days 3 to 10 | Zanubrutinib + Rifabutin on Day 11 |
|---|---|---|---|
| ChromaturiaRenal and urinary disorders | 0/13 | 6/13 | 0/13 |
| Vessel puncture site haematomaGeneral disorders | 1/13 | 0/13 | 0/13 |
| Age, Continuous(Years) | Zanubrutinib + Rifabutin |
|---|---|
| Mean | 48.8 ± 11.00 |
| Sex: Female, Male(Participants) | Zanubrutinib + Rifabutin |
|---|---|
| Female | 0 |
| Male | 13 |
| Ethnicity (NIH/OMB)(Participants) | Zanubrutinib + Rifabutin |
|---|---|
| Hispanic or Latino | 8 |
| Not Hispanic or Latino | 5 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Zanubrutinib + Rifabutin |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 12 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Jul 2020 to primary completion in Nov 2020, 3 months.
Results were first posted in Dec 2023, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Zanubrutinib · Rifabutin